Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Prescott Atkinson

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Current Opinion in Rheumatology|July 24, 2012
Immune deficiency and autoimmunityThomas Prescott Atkinson
FEMS Microbiology Reviews|August 30, 2008
Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infectionsThomas Prescott Atkinson, Mitchell F Balish, Ken B Waites
Open Forum Infectious Diseases|July 17, 2015
Disseminated Primary Herpes Simplex Virus Type 2 Infection in a 22-Year-Old maleNathan Erdmann, Benjamin A Hewitt, Thomas Prescott Atkinson, et al.
Journal of Human Immunity|May 22, 2026
A compound heterozygous case of leukocyte adhesion deficiency type-1 with moderate CD18 expression and severe diseaseJeremy Richard Brozyna, Rosemary Moak, Loretta Modica Parker, et al.
Plos One|September 22, 2025
Surface protein glycosylation conserved in the human pathogen Mycoplasma genitalium and retained in the synthetic organism JCVI-Syn3AJohn William Sanford, James Mobley, Kevin Dybvig, et al.
Frontiers in Microbiology|August 18, 2022
Antimicrobial susceptibilities and mechanisms of resistance of commensal and invasive <i>Mycoplasma salivarium</i> isolatesLi Xiao, Arthur H Totten, Donna M Crabb, et al.
The Journal of Rheumatology|August 17, 2013
High doses of infliximab in the management of juvenile idiopathic arthritisAjay Tambralli, Timothy Beukelman, Peter Weiser, et al.
Pediatrics|September 7, 2019
<i>Mycoplasma pneumoniae</i> Carriage With De Novo Macrolide-Resistance and Breakthrough PneumoniaAmmar Saadoon Alishlash, Thomas Prescott Atkinson, Charles Schlappi, et al.
Immunotherapy|May 6, 2021
Treatment of children with primary immunodeficiencies with a subcutaneous immunoglobulin 16.5% (cutaquig<sup>®</sup> [octanorm])Roger H Kobayashi, Jose Fernando Mandujano, Syed M Rehman, et al.
Frontiers in Immunology|February 20, 2019
Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary ImmunodeficienciesRoger H Kobayashi, Sudhir Gupta, Isaac Melamed, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Current Opinion in Rheumatology|July 24, 2012
Immune deficiency and autoimmunityThomas Prescott Atkinson
FEMS Microbiology Reviews|August 30, 2008
Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infectionsThomas Prescott Atkinson, Mitchell F Balish, Ken B Waites
Open Forum Infectious Diseases|July 17, 2015
Disseminated Primary Herpes Simplex Virus Type 2 Infection in a 22-Year-Old maleNathan Erdmann, Benjamin A Hewitt, Thomas Prescott Atkinson, et al.
Journal of Human Immunity|May 22, 2026
A compound heterozygous case of leukocyte adhesion deficiency type-1 with moderate CD18 expression and severe diseaseJeremy Richard Brozyna, Rosemary Moak, Loretta Modica Parker, et al.
Plos One|September 22, 2025
Surface protein glycosylation conserved in the human pathogen Mycoplasma genitalium and retained in the synthetic organism JCVI-Syn3AJohn William Sanford, James Mobley, Kevin Dybvig, et al.
Frontiers in Microbiology|August 18, 2022
Antimicrobial susceptibilities and mechanisms of resistance of commensal and invasive <i>Mycoplasma salivarium</i> isolatesLi Xiao, Arthur H Totten, Donna M Crabb, et al.
The Journal of Rheumatology|August 17, 2013
High doses of infliximab in the management of juvenile idiopathic arthritisAjay Tambralli, Timothy Beukelman, Peter Weiser, et al.
Pediatrics|September 7, 2019
<i>Mycoplasma pneumoniae</i> Carriage With De Novo Macrolide-Resistance and Breakthrough PneumoniaAmmar Saadoon Alishlash, Thomas Prescott Atkinson, Charles Schlappi, et al.
Immunotherapy|May 6, 2021
Treatment of children with primary immunodeficiencies with a subcutaneous immunoglobulin 16.5% (cutaquig<sup>®</sup> [octanorm])Roger H Kobayashi, Jose Fernando Mandujano, Syed M Rehman, et al.
Frontiers in Immunology|February 20, 2019
Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary ImmunodeficienciesRoger H Kobayashi, Sudhir Gupta, Isaac Melamed, et al.
Pageof 2